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EXPERIMENTAL METHODS
mSA2, mRFP1, Cre Recombinase, transcription factors, antibiotic resistance proteins and PTDs were cloned, fused and expressed in/purified from E.coli using GST affinity chromatography. Cells were as described 1 . Flow cytometry used a MoFlo TM DP (DAKO) using a 488nm green laser. Cre assays used NIH3t3: LSL-eGFP cells created in-house. Biotinylated Abs were delivered using recombinant mSA2 by simple mixing and addition to cells. Nucleic acids and MNPs were delivered using chemically synthesised peptides with complexation by incubation and cell addition.
RESULTS AND DISCUSSION
To overcome the inefficiencies in delivery of biologically-active PTD-conjugates, we developed a multi-domain protein comprising a GAG-binding peptide to stimulate cell interaction and a PTD for high efficiency membrane transduction. We showed this GET (GAG-binding enhanced transduction) system could deliver enzymes (Cre, neomycin phosphotransferase), transcription factors (NANOG, MYOD), antibodies, native proteins (Antibodies, Cytochrome-C) (Figure 1a ), nucleic acids (plasmid (p)DNA, modified (mod)RNA and siRNA) (Figure 1b) , and magnetic nanoparticles (MNPs) (Figure 1c ) and at efficiencies of up to two-orders of magnitude higher than previously reported in cell types considered hard to transduce, such as mouse embryonic stem cells (mESCs), human ESCs (hESCs) and induced pluripotent stem cells (hiPSCs). We demonstrated that the GET system can be harnessed to promote survival, self-renewal or direct the differentiation of pluripotent cells toward a desired lineage. Furthermore other proteins can be delivered by coupling to GET peptides (such as antibodies) and this can be extended to other chemically distinct targets such as nucleic acids or MNPs. This system is not technically complex, as for modified RNA systems 12 , and offers several key advantages over established techniques to deliver the exogenous function of a gene, protein or delivering other reagents. GET technology may also be directly applied to reprogramming and programming technologies. Furthermore the delivery of DNA, RNA, siRNA and MNPs by GET enables its use for genome-editing, gene knockdown and for physical manipulation or imaging of cells, respectively. This technology represents an efficient strategy for controlling cell labelling, and directing cell fate or behaviour that has broad applicability for basic research, disease modelling and clinical application.
CONCLUSION
Our discovery that promoting heparan sulfate interaction significantly and synergistically improves the efficiency of PTD-tagged biologically active, macromolecular cargo will open up new avenues for the treatment, imaging and experimental investigation of disease. We believe that our improvement of the longestablished PTD technologies has the potential to become a major enabling technology for cellbased therapies and regenerative medicine.
